{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:30:16Z","timestamp":1778776216727,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.leukres.2021.106512","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T11:18:20Z","timestamp":1611055100000},"page":"106512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["The prognostic importance of BCR-ABL transcripts in Chronic Myeloid Leukemia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"101","author":[{"given":"Omid Kiani","family":"Ghalesardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebrahim","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1227-491X","authenticated-orcid":false,"given":"Seyed Esmaeil","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Hajifathali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Bonakchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoo","family":"Shahidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2021.106512_bib0005","article-title":"A minute chromosome in human chronic granulocytic leukemia","author":"Nowell","year":"1960","journal-title":"Science (80-.)"},{"key":"10.1016\/j.leukres.2021.106512_bib0010","doi-asserted-by":"crossref","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2021.106512_bib0015","doi-asserted-by":"crossref","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","author":"Lugo","year":"1990","journal-title":"Science (80-.)"},{"key":"10.1016\/j.leukres.2021.106512_bib0020","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106512_bib0025","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V75.5.1146.1146","article-title":"Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript","author":"Selleri","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106512_bib0030","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V88.7.2410.bloodjournal8872410","article-title":"Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR\/ABL with C3\/A2 junction)","author":"Pane","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106512_bib0035","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2021.106512_bib0040","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106512_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2021.106512_bib0050","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V98.7.2039","article-title":"Chronic myeloid leukemia: current treatment options","volume":"98","author":"Goldman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106512_bib0055","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106512_bib0060","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","author":"Chereda","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2021.106512_bib0065","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106512_bib0070","doi-asserted-by":"crossref","DOI":"10.1586\/14737140.4.1.85","article-title":"Clinical and epidemiologic burden of chronic myelogenous leukemia","author":"Redaelli","year":"2004","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.leukres.2021.106512_bib0075","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","author":"H\u00f6glund","year":"2015","journal-title":"Ann. Hematol."},{"issue":"October 10","key":"10.1016\/j.leukres.2021.106512_bib0080","first-page":"1648","article-title":"Chronic myeloid leukemia, BCR\/ABL transcript, response to alpha-interferon and survival. The Italian Cooperative Study Group on Chronic Myeloid Leukemia","volume":"9","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2021.106512_bib0085","article-title":"Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia","author":"Rozman","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2021.106512_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(00)00128-3","article-title":"The possible influences of B2A2 and B3A2 BCR\/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia","author":"Perego","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.leukres.2021.106512_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/S0165-4608(01)00515-5","article-title":"BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador, South America","author":"Paz-y-Mio","year":"2002","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.leukres.2021.106512_bib0100","doi-asserted-by":"crossref","DOI":"10.1159\/000093641","article-title":"Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants","author":"Auewarakul","year":"2006","journal-title":"Acta Haematol."},{"key":"10.1016\/j.leukres.2021.106512_bib0105","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.20682","article-title":"Molecular profiling of chronic myeloid leukemia in Eastern India","author":"Mondal","year":"2006","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2021.106512_bib0110","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0609.2008.01170.x","article-title":"Correlation of BCR\/ABL transcript variants with patients\u2019 characteristics in childhood chronic myeloid leukaemia","author":"Adler","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2021.106512_bib0115","doi-asserted-by":"crossref","DOI":"10.4238\/vol7-4gmr485","article-title":"Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr\/Abl fusion transcripts","author":"Polampalli","year":"2008","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.leukres.2021.106512_bib0120","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2009.009134","article-title":"Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript","author":"Lucas","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2021.106512_bib0125","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-009-0822-7","article-title":"Response to imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts","author":"Sharma","year":"2010","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2021.106512_bib0130","doi-asserted-by":"crossref","DOI":"10.1590\/S1415-47572010005000037","article-title":"Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients","author":"Osman","year":"2010","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.leukres.2021.106512_bib0135","doi-asserted-by":"crossref","DOI":"10.4103\/0971-5916.93423","article-title":"Cytogenetic & molecular analyses in adult chronic myelogenous leukaemia patients in north India","author":"Anand","year":"2012","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.leukres.2021.106512_bib0140","article-title":"Correlation between the type of bcr-abl transcripts and blood cell counts in chronic myeloid leukemia - a possible influence of mdr1 gene expression","author":"Balatzenko","year":"2011","journal-title":"Hematol. Rev. Sov. Med. Rev."},{"key":"10.1016\/j.leukres.2021.106512_bib0145","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-012-0348-z","article-title":"Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia","author":"Bennour","year":"2013","journal-title":"Med. Oncol."},{"key":"10.1016\/j.leukres.2021.106512_bib0150","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.23427","article-title":"Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib","author":"Lee","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2021.106512_bib0155","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2021.106512_bib0160","article-title":"Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: their correlation with presenting features, risk scores and response to treatment with imatinib mesylate","author":"Deb","year":"2014","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"10.1016\/j.leukres.2021.106512_bib0165","doi-asserted-by":"crossref","first-page":"328","DOI":"10.33145\/2304-8336-2015-20-328-340","article-title":"Assessment of response to imatinib therapy in patients with chronic myeloid leukemia with e13a2 and e14a2 transcripts of BCR\/ABL1 gene","volume":"20","author":"Dmytrenko","year":"2015","journal-title":"Probl. Radiatsiinoi Medytsyny Ta Radiobiolohii"},{"key":"10.1016\/j.leukres.2021.106512_bib0170","article-title":"Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients","author":"Al-Achkar","year":"2016","journal-title":"J. BUON"},{"key":"10.1016\/j.leukres.2021.106512_bib0175","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.12597","article-title":"Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia","author":"Lin","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2021.106512_bib0180","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2021.106512_bib0185","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8420853","article-title":"Frequency of BCR-ABL transcript types in syrian CML patients","author":"Farhat-Maghribi","year":"2016","journal-title":"J. Oncol."},{"key":"10.1016\/j.leukres.2021.106512_bib0190","doi-asserted-by":"crossref","DOI":"10.1111\/ijlh.12616","article-title":"Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients","author":"Arun","year":"2017","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.leukres.2021.106512_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2017.06.018","article-title":"Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia","author":"Rostami","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.leukres.2021.106512_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.trsl.2006.07.002","article-title":"Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR","author":"Goh","year":"2006","journal-title":"Transl. Res."},{"key":"10.1016\/j.leukres.2021.106512_bib0205","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ajh.24774","article-title":"The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2021.106512_bib0210","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.168740","article-title":"E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy","author":"Claudiani","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2021.106512_bib0215","doi-asserted-by":"crossref","DOI":"10.4238\/gmr16029541","article-title":"BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia","author":"Vasconcelos","year":"2017","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.leukres.2021.106512_bib0220","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2017.1320711","article-title":"Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy","author":"Lee","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2021.106512_bib0225","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-016-2321-2","article-title":"No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib","author":"Pfirrmann","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.leukres.2021.106512_bib0230","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.clml.2017.06.009","article-title":"Influence of BCR-ABL transcript type on outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"17","author":"Pagnano","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2021.106512_bib0235","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4103\/ijmpo.ijmpo_80_17","article-title":"Assessment of BCR-ABL1 fusion transcripts and their association with response to imatinib treatment in chronic myeloid leukemia patients","volume":"39","author":"Kagita","year":"2018","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"10.1016\/j.leukres.2021.106512_bib0240","doi-asserted-by":"crossref","DOI":"10.1007\/s12291-018-0779-1","article-title":"A prognostic and predictive study of BCR-ABL expression based on characterization of fusion transcripts","author":"Upadhyay","year":"2020","journal-title":"Indian J. Clin. Biochem."},{"key":"10.1016\/j.leukres.2021.106512_bib0245","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2021.106512_bib0250","doi-asserted-by":"crossref","DOI":"10.1007\/BF01630378","article-title":"The minute chromosome (Ph1) in chronic granulocytic leukemia","author":"Nowell","year":"1962","journal-title":"Blut Zeitschrift F\u00fcr Die Gesamte Blutforsch."},{"key":"10.1016\/j.leukres.2021.106512_bib0255","article-title":"Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission","author":"Serpa","year":"2010","journal-title":"BMC Blood Disord."},{"key":"10.1016\/j.leukres.2021.106512_bib0260","doi-asserted-by":"crossref","DOI":"10.5581\/1516-8484.20110056","article-title":"Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response","author":"Machado","year":"2011","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"10.1016\/j.leukres.2021.106512_bib0265","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.31977","article-title":"The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors","author":"D\u2019Adda","year":"2019","journal-title":"Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621000138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621000138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:54Z","timestamp":1758934854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621000138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":53,"alternative-id":["S0145212621000138"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106512","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prognostic importance of BCR-ABL transcripts in Chronic Myeloid Leukemia: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106512"}}